Background Lopinavir–ritonavir has been proposed as a treatment for COVID-19 on the
basis of in vitro activity, preclinical studies, and observational studies. Here, we report the …

Introduction: The therapeutic impact of molnupiravir in the Omicron variant phase is
unknown. The goal of the current meta-analysis was to compare the real-world clinical …

Objectives AGILE is a Phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In
this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in …

Background: In the EPIC-HR (Evaluation of Protease Inhibition for Covid-19 in High-Risk
Patients) trial, nirmatrelvir plus ritonavir led to an 89% reduction in hospitalization or death …

Background Nirmatrelvir is a protease inhibitor with in-vitro activity against SARS-CoV-2,
and ritonavir-boosted nirmatrelvir can reduce the risk of progression to severe COVID-19 …

ABSTRACT Background In the United States, oral nirmatrelvir-ritonavir (Paxlovid™) is
authorized for use among patients aged≥ 12 years with mild-to-moderate SARS-CoV-2 …

Vaccines and drugs are the cornerstones in the fight against the SARS‐CoV‐2 pandemic.
While vaccines were a success story, the development of antiviral drugs against SARS‐CoV …

The first Polish recommendations regarding the management of patients with COVID-19
were published by the Polish Society of Epidemiologists and Infectiologists (PTEiLChZ) on …

Background The role of molnupiravir for coronavirus disease 2019 (COVID-19) treatment is
unclear. Methods We conducted a systematic review until 1 November 2022 searching for …

For LPV, the steady-state total minimum plasma concentration (Cmin) at the standard HIV-1
treatment dose of 400/100 mg LPV/r is approximately 5 g/ml, or 0.075 g/ml of unbound (free) …